Light and dark of reactive oxygen species for vascular function: 2014 ASVB (Asian Society of Vascular Biology)

Journal of Cardiovascular Pharmacology

Volumn 65, Issue 5, 2015, Pages 412-418

  Shimokawa, Hiroaki ^a   Satoh, Kimio ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

reactive oxygen species; Rho kinase; vascular diseases; vascular homeostasis

Indexed keywords

CYCLOPHILIN A; HYDROGEN PEROXIDE; REACTIVE OXYGEN METABOLITE; RHO KINASE; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; AUTACOID; CARDIOVASCULAR AGENT; PROTEIN KINASE INHIBITOR;

ARTERIOSCLEROSIS; ARTICLE; BLOOD VESSEL FUNCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CELL DAMAGE; CELL FUNCTION; CEREBROVASCULAR ACCIDENT; HEART FAILURE; HUMAN; HYPERTENSION; INFLAMMATION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SECRETION; PULMONARY HYPERTENSION; REPERFUSION INJURY; VASCULAR DISEASE; VASOSPASM; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD VESSEL; CARDIOVASCULAR DISEASES; DRUG EFFECTS; METABOLISM; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BLOOD VESSELS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CYCLOPHILIN A; HUMANS; HYDROGEN PEROXIDE; INFLAMMATION MEDIATORS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION;

EID: 84930210239     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000159     Document Type: Article

References (108)

1. Shimokawa H, Tomoike H, Nabeyama S, et al. Coronary artery spasm induced in atherosclerotic miniature swine. Science. 1983;221:560-562
2. Shimokawa H. Primary endothelial dysfunction: atherosclerosis. J Mol Cell Cardiol. 1999;31:23-37
3. Vanhoutte PM. Endothelium-derived free radicals: for worse and for better. J Clin Invest. 2001;107:23-25
4. Matoba T, Shimokawa H, Nakashima M, et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest. 2000;106:1521-1530
5. Morikawa K, Shimokawa H, Matoba T, et al. Pivotal role of Cu,Znsuperoxide dismutase in endothelium-dependent hyperpolarization. J Clin Invest. 2003;112:1871-1879
6. Takaki A, Morikawa K, Tsutsui M, et al. Crucial role of nitric oxide synthases system in endothelium-dependent hyperpolarization in mice. J Exp Med. 2008;205:2053-2063
7. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension. 2003;42: 1075-1081
8. Sandow SL. Factors, fiction and endothelium-derived hyperpolarizing factor. Clin Exp Pharmacol Physiol. 2004;31:563-570
9. Shao D, Oka S, Brady CD, et al. Redox modification of cell signaling in the cardiovascular system. J Mol Cell Cardiol. 2012;52:550-558
10. Takaki A, Morikawa K, Murayama Y, et al. Roles of endothelial oxidases in endothelium-derived hyperpolarizing factor responses in mice. J Cardiovasc Pharmacol. 2008;52:510-517
11. Satoh K, Godo S, Saito H, et al. Dual roles of vascular-derived reactive oxygen species-With a special reference to hydrogen peroxide and cyclophilin A. J Mol Cell Cardiol. 2014;73C:50-56
12. Cohen RA, Adachi T. Nitric-oxide-induced vasodilatation: regulation by physiologic s-glutathiolation and pathologic oxidation of the sarcoplasmic endoplasmic reticulum calcium ATPase. Trends Cardiovasc Med. 2006;16:109-114
13. Wu C, Parrott AM, Fu C, et al. Thioredoxin 1-mediated posttranslational modifications: reduction, transnitrosylation, denitrosylation, and related proteomics methodologies. Antioxid Redox Signal. 2011;15:2565-2604
14. Vanhoutte PM, Shimokawa H, Tang EH, et al. Endothelial dysfunction and vascular disease. Acta Physiol (Oxf). 2009;196:193-222
15. Shimokawa H. Hydrogen peroxide as an endothelium-derived hyperpolarizing factor. Pflugers Arch. 2010;459:915-922
16. Feletou M, Vanhoutte PM. Endothelium-dependent hyperpolarization of canine coronary smooth muscle. Br J Pharmacol. 1988;93:515-524
17. Chen G, Suzuki H, Weston AH. Acetylcholine releases endotheliumderived hyperpolarizing factor and EDRF from rat blood vessels. Br J Pharmacol. 1988;95:1165-1174
18. Prysyazhna O, Rudyk O, Eaton P. Single atom substitution in mouse protein kinase G eliminates oxidant sensing to cause hypertension. Nat Med. 2012;18:286-290
19. Feletou M, Vanhoutte PM. Endothelium-dependent hyperpolarizations: past beliefs and present facts. Ann Med. 2007;39:495-516
20. Burgoyne JR, Madhani M, Cuello F, et al. Cysteine redox sensor in PKGIa enables oxidant-induced activation. Science. 2007;317: 1393-1397
21. Burgoyne JR, Prysyazhna O, Rudyk O, et al. cGMP-dependent activation of protein kinase G precludes disulfide activation: implications for blood pressure control. Hypertension. 2012;60:1301-1308
22. Ohashi J, Sawada A, Nakajima S, et al. Mechanisms for enhanced endothelium-derived hyperpolarizing factor-mediated responses in microvessels in mice. Circ J. 2012;76:1768-1779
23. Nakajima S, Ohashi J, Sawada A, et al. Essential role of bone marrow for microvascular endothelial and metabolic functions in mice. Circ Res. 2012;111:87-96
24. Fleming I, Michaelis UR, Bredenkotter D, et al. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res. 2001;88:44-51
25. Griendling KK, Minieri CA, Ollerenshaw JD, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148
26. Lassegue B, San MA, Griendling K. Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res. 2012;110:1364-1390
27. Nishida M, Hara Y, Yoshida T, et al. TRP channels: molecular diversity and physiological function. Microcirculation. 2006;13:535-550
28. Shimizu S, Takahashi N, Mori Y. TRPs as Chemosensors (ROS, RNS, RCS, Gasotransmitters). Handb Exp Pharmacol. 2014;223:767-794
29. Vanhoutte PM. Say NO to ET. J Auton Nerv Syst. 2000;81:271-277
30. Yang D, Feletou M, Boulanger CM, et al. Oxygen-derived free radicals mediate endothelium-dependent contractions to acetylcholine in aortas from spontaneously hypertensive rats. Br J Pharmacol. 2002; 136:104-110
31. Shimokawa H. Reactive oxygen species promote vascular smooth muscle cell proliferation. Circ Res. 2013;113:1040-1042
32. Satoh K, Fukumoto Y, Shimokawa H. Rho-kinase: important new therapeutic target in cardiovascular diseases. Am J Physiol Heart Circ Physiol. 2011;301:H287-H296
33. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 2002;420:629-635
34. Schmidt A, Hall A. Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. Genes Dev. 2002;16:1587-1609
35. Bernards A. GAPs galore A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. Biochim Biophys Acta. 2003;1603:47-82
36. Olofsson B. Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. Cell Signal. 1999;11:545-554
37. Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science. 1996;273: 245-248
38. Amano M, Ito M, Kimura K, et al. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem. 1996;271: 20246-20249
39. Berk BC, Alexander RW, Brock TA, et al. Vasoconstriction: a new activity for platelet-derived growth factor. Science. 1986;232:87-90
40. Griendling KK, Berk BC, Ganz P, et al. Angiotensin II stimulation of vascular smooth muscle phosphoinositide metabolism. State of the art lecture. Hypertension. 1987;9:III181-185
41. Berk BC. Vascular smooth muscle growth: autocrine growth mechanisms. Physiol Rev. 2001;81:999-1030
42. Suzuki J, Jin ZG, Meoli DF, et al. Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle cells. Circ Res. 2006; 98:811-817
43. Satoh K, Fukumoto Y, Nakano M, et al. Statin ameliorates hypoxiainduced pulmonary hypertension associated with down-regulated stromal cell-derived factor-1. Cardiovasc Res. 2009;81:226-234
44. Nigro P, Satoh K, O'Dell MR, et al. Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice. J Exp Med. 2011;208:53-66
45. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol. 2005;25:1767-1775
46. Higashi M, Shimokawa H, Hattori T, et al. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res. 2003;93:767-775
47. Funakoshi Y, Ichiki T, Shimokawa H, et al. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension. 2001;38: 100-104
48. Takeda K, Ichiki T, Tokunou T, et al. Critical role of Rho-kinase and MEK/ERK pathways for angiotensin II-induced plasminogen activator inhibitor type-1 gene expression. Arterioscler Thromb Vasc Biol. 2001; 21:868-873
49. Guilluy C, Bregeon J, Toumaniantz G, et al. The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. Nat Med. 2010;16:183-190
50. van Nieuw Amerongen GP, van Delft S, Vermeer MA, et al. Activation of RhoA by thrombin in endothelial hyperpermeability: role of Rhokinase and protein tyrosine kinases. Circ Res. 2000;87:335-340
51. Seasholtz TM, Majumdar M, Kaplan DD, et al. Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res. 1999;84:1186-1193
52. Kishi H, Bao J, Kohama K. Inhibitory effects of ML-9, wortmannin, and Y-27632 on the chemotaxis of vascular smooth muscle cells in response to platelet-derived growth factor-BB. J Biochem. 2000;128: 719-722
53. Sauzeau V, Le Jeune H, Cario-Toumaniantz C, et al. P2Y(1), P2Y(2), P2Y(4), and P2Y(6) receptors are coupled to Rho and Rho kinase activation in vascular myocytes. Am J Physiol Heart Circ Physiol. 2000;278:H1751-H1761
54. Sauzeau V, Le Mellionnec E, Bertoglio J, et al. Human urotensin IIinduced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res. 2001;88:1102-1104
55. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21: 1712-1719
56. Rashid M, Tawara S, Fukumoto Y, et al. Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors. Circ J. 2009;73:361-370
57. Tanaka S, Fukumoto Y, Nochioka K, et al. Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation. Arterioscler Thromb Vasc Biol. 2013;33:1591-1600
58. Satoh K, Matoba T, Suzuki J, et al. Cyclophilin A mediates vascular remodeling by promoting inflammation and vascular smooth muscle cell proliferation. Circulation. 2008;117:3088-3098
59. Shimokawa H. Cellular and molecular mechanisms of coronary artery spasm: lessons from animal models. Jpn Circ J. 2000;64:1-12
60. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol. 2002;39:319-327
61. Amano M, Chihara K, Kimura K, et al. Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science. 1997;275: 1308-1311
62. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279: 509-514
63. Jin ZG, Melaragno MG, Liao DF, et al. Cyclophilin A is a secreted growth factor induced by oxidative stress. Circ Res. 2000;87:789-796
64. Satoh K, Nigro P, Berk BC. Oxidative stress and vascular smooth muscle cell growth: a mechanistic linkage by cyclophilin A. Antioxid Redox Signal. 2010;12:675-682
65. Satoh K, Shimokawa H, Berk BC. Cyclophilin A: promising new target in cardiovascular therapy. Circ J. 2010;74:2249-2256
66. Mackay DJ, Hall A. Rho GTPases. J Biol Chem. 1998;273:20685-20688
67. Neco P, Giner D, Viniegra S, et al. New roles of myosin II during vesicle transport and fusion in chromaffin cells. J Biol Chem. 2004; 279:27450-27457
68. Jin ZG, Lungu AO, Xie L, et al. Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Arterioscler Thromb Vasc Biol. 2004;24:1186-1191
69. Kim H, Kim WJ, Jeon ST, et al. Cyclophilin A may contribute to the inflammatory processes in rheumatoid arthritis through induction of matrix degrading enzymes and inflammatory cytokines from macrophages. Clin Immunol. 2005;116:217-224
70. Damsker JM, Bukrinsky MI, Constant SL. Preferential chemotaxis of activated human CD4+ T cells by extracellular cyclophilin A. J Leukoc Biol. 2007;82:613-618
71. Yang Y, Lu N, Zhou J, et al. Cyclophilin A up-regulates MMP-9 expression and adhesion of monocytes/macrophages via CD147 signalling pathway in rheumatoid arthritis. Rheumatology (Oxf). 2008;47: 1299-1310
72. Wang L, Wang CH, Jia JF, et al. Contribution of cyclophilin A to the regulation of inflammatory processes in rheumatoid arthritis. J Clin Immunol. 2010;30:24-33
73. Shimokawa H, Rashid M. Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci. 2007;28:296-302
74. Eto Y, Shimokawa H, Hiroki J, et al. Gene transfer of dominant negative Rho-kinase suppresses neointimal formation after balloon injury in pigs. Am J Physiol Heart Circ Physiol. 2000;278:H1744-H1750
75. Ikeda S, Satoh K, Kikuchi N, et al. Crucial role of rho-kinase in pressure overload-induced right ventricular hypertrophy and dysfunction in mice. Arterioscler Thromb Vasc Biol. 2014;34:1260-1271
76. Sawada N, Itoh H, Ueyama K, et al. Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation. 2000;101:2030-2033
77. Shibata R, Kai H, Seki Y, et al. Role of Rho-associated kinase in neointima formation after vascular injury. Circulation. 2001;103:284-289
78. Shimokawa H, Ito A, Fukumoto Y, et al. Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. J Clin Invest. 1996;97:769-776
79. Shimokawa H, Morishige K, Miyata K, et al. Long-term inhibition of Rho-kinase induces a regression of arteriosclerotic coronary lesions in a porcine model in vivo. Cardiovasc Res. 2001;51:169-177
80. Matsumoto Y, Uwatoku T, Oi K, et al. Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: involvement of multiple mechanisms. Arterioscler Thromb Vasc Biol. 2004;24:181-186
81. Hattori T, Shimokawa H, Higashi M, et al. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation. 2004;109:2234-2239
82. Takagi Y, Yasuda S, Takahashi J, et al. Importance of dual induction tests for coronary vasospasm and ventricular fibrillation in patients surviving out-of-hospital cardiac arrest. Circ J. 2009;73:767-769
83. Hizume T, Morikawa K, Takaki A, et al. Sustained elevation of serum cortisol level causes sensitization of coronary vasoconstricting responses in pigs in vivo: a possible link between stress and coronary vasospasm. Circ Res. 2006;99:767-775
84. Katsumata N, Shimokawa H, Seto M, et al. Enhanced myosin light chain phosphorylations as a central mechanism for coronary artery spasm in a swine model with interleukin-1b. Circulation. 1997;96: 4357-4363
85. Shimokawa H, Seto M, Katsumata N, et al. Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res. 1999;43:1029-1039
86. Masumoto A, Mohri M, Shimokawa H, et al. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation. 2002;105:1545-1547
87. Mohri M, Shimokawa H, Hirakawa Y, et al. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J Am Coll Cardiol. 2003;41:15-19
88. Shimokawa H, Hiramori K, Iinuma H, et al. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol. 2002;40:751-761
89. Kikuchi Y, Yasuda S, Aizawa K, et al. Enhanced Rho-kinase activity in circulating neutrophils of patients with vasospastic angina: a possible biomarker for diagnosis and disease activity assessment. J Am Coll Cardiol. 2011;58:1231-1237
90. Nihei T, Takahashi J, Kikuchi Y, et al. Enhanced Rho-kinase activity in patients with vasospastic angina after the Great East Japan Earthquake. Circ J. 2012;76:2892-2894
91. Tsuburaya R, Yasuda S, Shiroto T, et al. Long-term treatment with nifedipine suppresses coronary hyperconstricting responses and inflammatory changes induced by paclitaxel-eluting stent in pigs in vivo: possible involvement of Rho-kinase pathway. Eur Heart J. 2012;33: 791-799
92. Nihei T, Takahashi J, Tsuburaya R, et al. Circadian variation of Rhokinase activity in circulating leukocytes of patients with vasospastic angina. Circ J. 2014;78:1183-1190
93. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res. 2006; 99:675-691
94. Satoh K, Kagaya Y, Nakano M, et al. Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation. 2006; 113:1442-1450
95. Shimizu T, Fukumoto Y, Tanaka S, et al. Crucial role of ROCK2 in vascular smooth muscle cells for hypoxia-induced pulmonary hypertension in mice. Arterioscler Thromb Vasc Biol. 2013;33:2780-2791
96. Elias-Al-Mamun M, Satoh K, Tanaka S, et al. Combination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension and survival in rats. Circ J. 2014;78:967-976
97. Liao DF, Jin ZG, Baas AS, et al. Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. J Biol Chem. 2000;275:189-196
98. Khromykh LM, Kulikova NL, Anfalova TV, et al. Cyclophilin A produced by thymocytes regulates the migration of murine bone marrow cells. Cell Immunol. 2007;249:46-53
99. Abe K, Shimokawa H, Morikawa K, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res. 2004;94:385-393
100. Abe K, Tawara S, Oi K, et al. Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice. J Cardiovasc Pharmacol. 2006;48:280-285
101. Do e Z, Fukumoto Y, et al. Evidence for Rho-kinase activation in patients with pulmonary arterial hypertension. Circ J. 2009;73:1731-1739
102. Fukumoto Y, Matoba T, Ito A, et al. Acute vasodilator effects of a Rhokinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart. 2005;91:391-392
103. Fukumoto Y, Yamada N, Matsubara H, et al. Double-blind, placebocontrolled clinical trial with a rho-kinase inhibitor in pulmonary arterial hypertension. Circ J. 2013;77:2619-2625
104. Soe NN, Sowden M, Baskaran P, et al. Cyclophilin A is required for angiotensin II-induced p47phox translocation to caveolae in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2013;33:2147-2153
105. Pushkarsky T, Zybarth G, Dubrovsky L, et al. CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A. Proc Natl Acad Sci USA. 2001;98:6360-6365
106. Satoh K, Fukumoto Y, Sugimura K, et al. Plasma Cyclophilin A is a novel biomarker for coronary artery disease. Circ J. 2013;77:447-455
107. Weintraub NL. Understanding abdominal aortic aneurysm. N Engl J Med. 2009;361:1114-1116
108. Shimokawa H. 2014 Williams Harvey Lecture: importance of coronary vasomotion abnormalities-from bench to bedside. Eur Heart J. 2014 (in press